Valneva SE announced on June 5, 2025, positive six-month antibody persistence and safety data from its Phase 2 clinical trial for the single-shot chikungunya vaccine, IXCHIQ®, in 304 children. The results were consistent with initial data reported in January 2025, showing a full dose elicited a robust immune response.
The study confirmed a strong immune response in CHIKV-naïve children, with a 96.5% seroresponse rate at Day 180 for the full dose. The vaccine was well tolerated across all age groups tested in children, with no safety concerns identified, supporting the selection of the full dose for future development.
These data are aligned with the robust antibody response and safety profile observed in adolescents and adults, reinforcing IXCHIQ®'s potential to offer long-term protection with a single shot. The company expects to initiate a pivotal Phase 3 study in children in the first quarter of 2026, aiming to extend the product label to this age group.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.